Back to results
US 11,376,264 B2Granted
Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment
AssigneeThe Salk Institute for Biological Studies
InventorsRonald M. Evans, Michael Downes, Zong Wei, Annette Atkins, Ruth T. Yu
Life of this patent
Estimating the term…
Abstract
Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.
Claims18
A method of reducing blood glucose in a mammal, comprising:
- administering a therapeutically effective amount of one or more vitamin D receptor (VDR) agonists to the mammal, wherein the one or more VDR agonists is calcipotriol, 25-hydroxy-D3 (25-OH-D3) (calcidiol);
- vitamin D3 (cholecalciferol);
- vitamin D2 (ergocalciferol), 1α,25-dihydroxyvitamin D3 (calcitriol), or a combination thereof, and
- administering a therapeutically effective amount of one or more bromodomain-containing protein 9 (BRD9) antagonists to the mammal, wherein the one or more BRD9) antagonists is I-BRD-9, TP742, BI-7273, BI-9564, dBRD9, GNE-375, LP-99, or a combination thereof,
- thereby reducing blood glucose in the mammal.
2 more elements
A method of treating type 2 diabetes in a mammal, comprising:
- administering a therapeutically effective amount of one or more vitamin D receptor (VDR) agonists to the mammal, wherein the one or more VDR agonists is calcipotriol, 25-hydroxy-D3 (25-OH-D3) (calcidiol);
- vitamin D3 (cholecalciferol):
- vitamin D2 (ergocalciferol), 1α,25-dihydroxyvitamin D3 (calcitriol), or a combination thereof, and
- administering a therapeutically effective amount of one or more bromodomain-containing protein 9 (BRD9) antagonists to the mammal, wherein the one or more BRD9) antagonists is I-BRD-9, TP742, BI-7273, BI-9564, dBRD9, GNE-375, LP-99, or a combination thereof,
- thereby treating type 2 diabetes in the mammal.
2 more elements
A method, comprising:
- administering a therapeutically effective amount of one or more vitamin D receptor (VDR) agonists to a mammal, wherein the one or more VDR agonists is calcipotriol, 25-hydroxy-D3 (25-OH-D3) (calcidiol);
- vitamin D3 (cholecalciferol);
- vitamin D2 (ergocalciferol), 1α,25-dihydroxyvitamin D3 (calcitriol), or a combination thereof, and
- administering a therapeutically effective amount of one or more bromodomain-containing protein 9 (BRD9) antagonists to the mammal, wherein the one or more BRD9) antagonists is I-BRD-9, TP742, BI-7273, BI-9564, dBRD9, GNE-375, LP-99, or a combination thereof,
- wherein the method reduces fed and fasting blood glucose, increases insulin sensitivity, increases glucose tolerance, increases insulin secretion, increases beta cell function, increases the size of islets, reduced beta cell death, increases insulin granules, or combinations thereof, in the mammal.
2 more elements
Dependencies are inferred from the claim text.